论文部分内容阅读
目的研究高分级脑胶质瘤术后三维适行放疗联合恩度及尼莫司汀的有效性和安全性。方法选择我院收治的15例高分级脑胶质瘤术后患者行三维适行放疗,DT50gy-68Gy;同时静脉给予恩度15mg/d,连用14d;尼莫司汀90mg/m2,第1天给药;28d为1周期。以RECIST标准评价疗效,以NCI标准评价毒性反应。结果 15例患者均可评价客观疗效及毒副反应。CR53.3%,PR26.7%,SD13.3%,PD6.7%,RR(CR+PR)80.0%,DCR(CR+PR+SD)为93.3%。中位无进展生存时间14个月,1年和2年生存率分别为86.7%和60.0%。结论三维适行放疗联合联合恩度及尼莫司汀治疗高分级脑胶质瘤安全、有效。
Objective To investigate the efficacy and safety of three-dimensional adaptive radiotherapy combined with endostar and nimustine in patients with high grade gliomas. Methods Fifteen patients with high grade gliomas admitted to our hospital underwent postoperative three-dimensional radiotherapy, DT50gy-68Gy. At the same time, intravenous injection of Endeavor 15mg / d for 14 days and nimustine 90mg / m2 on day 1 Administration; 28d for a cycle. RECIST criteria to evaluate the efficacy of toxicity to evaluate the NCI standard response. Results All 15 patients were able to evaluate the objective efficacy and toxicity. CR53.3%, PR26.7%, SD13.3%, PD6.7%, RR (CR + PR) 80.0% and DCR (CR + PR + SD) 93.3%. The median progression-free survival time was 14 months, and the 1-year and 2-year survival rates were 86.7% and 60.0%, respectively. Conclusions Three-dimensional adaptive radiotherapy combined with enamel and nimustine in the treatment of high grade glioma is safe and effective.